IFNG and Huntington disease: In one large cohort of HD patients, the mean (95% CI) percent reduction in induced CMI, measured by IFN-γ secretion in response to antigen 2, from weeks 8/9 to 24 was −22.1% (−12.8% to −30.4%) and −45.9% (−38.5% to −52.4%) for dialysis patients who received two doses of BNT162b and mRNA-1273, respectively [27].